Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 0 of 100 as at 15 Aug 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Latigo Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (43): Smaller than most of the companies we track.
Volatility (0): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on LTGO, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LTGO appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 75% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 92% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Latigo Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Latigo Biotherapeutics (NASDAQ:LTGO) went public, receiving a strong reception from the market. The company is focused on developing a non-opioid pain treatment.
Why it matters — The IPO's warm welcome signals investor appetite for Latigo's non-opioid pain approach, making the company's public-market debut a notable event for LTGO watchers.
As at 15 Aug 2026, Latigo Biotherapeutics, Inc. ranks 0 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (43 of 100).
No analyst covering Latigo Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LTGO are extrapolating price history, which says nothing about the business.
Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines.
The most recent item we track (24/7 Wall Street, 13 Aug 2026): "Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public". Latigo Biotherapeutics (NASDAQ:LTGO) went public, receiving a strong reception from the market. The company is focused on developing a non-opioid pain treatment.
Latigo Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing non-opioid pain medicines. Its current programs center on NaV1.8 inhibitor candidates designed to reduce pain transmission without the addictive risks associated with traditional opioid therapies. The company’s pipeline includes oral and injectable approaches for acute pain as well as candidates aimed at chronic musculoskeletal pain, including osteoarthritis. Latigo Biotherapeutics Inc. operates in the biotechnology and life sciences markets, where it contributes to the broader shift toward targeted pain management therapies. Based in Thousand Oaks, California, the company is positioned as a specialist developer of precision medicines for pain relief across multiple treatment settings.
CEO Mr. Nima Farzan M.B.A. · 59 employees · United States · https://latigobio.com